# Filing Detail

Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-25-280166
Filing Date
2025-11-13
Accepted
2025-11-13 16:09:49
Documents
65
Period of Report
2025-09-30

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 10-Q | trvi-20250930.htm iXBRL | 10-Q | 2862874
2 | EX-10.1 | trvi-ex10_1.htm | EX-10.1 | 67372
3 | EX-31.1 | trvi-ex31_1.htm | EX-31.1 | 18073
4 | EX-32.1 | trvi-ex32_1.htm | EX-32.1 | 12307
5 | GRAPHIC | img64809683_0.jpg | GRAPHIC | 40168
| Complete submission text file | 0001193125-25-280166.txt |  | 10455431

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
6 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | trvi-20250930.xsd | EX-101.SCH | 1160057
68 | EXTRACTED XBRL INSTANCE DOCUMENT | trvi-20250930_htm.xml | XML | 2004806

Mailing Address 195 CHURCH STREET 16TH FLOOR NEW HAVEN CT 06510
Business Address 195 CHURCH STREET 16TH FLOOR NEW HAVEN CT 06510 203-304-2499
Trevi Therapeutics, Inc. (Filer) CIK: 0001563880 (see all company filings)

EIN.: 450834299 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38886 | Film No.: 251478516
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)